铁作为重症患者新兴治疗靶点
本文综述非转铁蛋白结合铁(NTBI,即催化铁)在重症患者中的作用。催化铁虽仅占血清铁很小比例,但通过催化活性氧生成促进氧化应激、激活巨噬细胞并促进病原体生长,参与ICU多种疾病的恶性循环。文章梳理ICU患者NTBI的常见来源及急性期短暂铁失调,概述临床证据显示其对患者结局的不良影响,并回顾靶向铁代谢蛋白、传统螯合治疗及肾脏替代治疗联合螯合治疗等策略。
要点
- 非转铁蛋白结合铁(催化铁)仅占血清铁很小比例,却通过催化活性氧生成促进氧化应激,在ICU疾病加重中起重要作用。
- 催化铁还可激活巨噬细胞并促进病原体生长,参与ICU多种疾病的恶性循环。
- ICU患者在疾病急性期存在多种NTBI常见来源,导致短暂铁失调。
- 综述概述了临床证据显示催化铁对ICU主要疾病患者结局的不良影响。
- 治疗策略包括靶向铁代谢相关蛋白、传统螯合治疗以及肾脏替代治疗联合螯合治疗。
适用人群与场景
- 重症监护病房(ICU)的重症患者,处于疾病急性期。
处置流程与药物剂量
- 靶向铁代谢相关蛋白。
- 传统螯合治疗。
- 肾脏替代治疗联合螯合治疗。
研究设计与关键结果
- 综述指出,非转铁蛋白结合铁(NTBI,即催化铁)仅占血清铁很小比例,但通过催化活性氧生成促进氧化应激、激活巨噬细胞并促进病原体生长,参与ICU多种疾病的加重。
- ICU患者存在多种NTBI常见来源,导致疾病急性期短暂铁失调,铁成为多种ICU病理(常为多因素)恶性循环的关键环节。
- 临床证据显示催化铁对ICU主要疾病患者结局有不良影响。
- 治疗策略包括靶向铁代谢相关蛋白、传统螯合治疗及肾脏替代治疗联合螯合治疗。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「对床旁实践的改变」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
The multiple roles of iron in the body have been known for decades, particularly its involvement in iron overload diseases such as hemochromatosis. More recently, compelling evidence has emerged regarding the critical role of non-transferrin bound iron (NTBI), also known as catalytic iron, in the care of critically ill patients in intensive care units (ICUs). These trace amounts of iron constitute a small percentage of the serum iron, yet they are heavily implicated in the exacerbation of diseases, primarily by catalyzing the formation of reactive oxygen species, which promote oxidative stress. Additionally, catalytic iron activates macrophages and facilitates the growth of pathogens. This review aims to shed light on this underappreciated phenomenon and explore the various common sources of NTBI in ICU patients, which lead to transient iron dysregulation during acute phases of disease. Iron serves as the linchpin of a vicious cycle in many ICU pathologies that are often multifactorial. The clinical evidence showing its detrimental impact on patient outcomes will be outlined in the major ICU pathologies. Finally, different therapeutic strategies will be reviewed, including the targeting of proteins involved in iron metabolism, conventional chelation therapy, and the combination of renal replacement therapy with chelation therapy.
参考来源
- Grange C, Lux F, Brichart T, et al. Iron as an emerging therapeutic target in critically ill patients. Crit Care. 2023. PMID: 38049866. doi:10.1186/s13054-023-04759-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。